Definium Therapeutics (DFTX) Change in Accured Expenses (2021 - 2026)
Definium Therapeutics (DFTX) posted quarterly Change in Accured Expenses of $3.0 million for Q1 2026, up 325.28% year-over-year from $704003.2 in Q1 2025, and up 224.38% quarter-over-quarter from $923000.0 in Q4 2025.
Powered by 
Analysis
Definium Therapeutics (DFTX) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Change in Accured Expenses for 6 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 325.28% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $10.3 million (up 129.64% YoY), while the FY2025 annual figure was $6.0 million, up 92.01% from the prior year.
- Change in Accured Expenses rose to $3.0 million in Q1 2026 per DFTX's latest filing, from $923000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $3.8 million in Q4 2024 and bottomed at -$2.7 million in Q1 2024.
- Historically, Change in Accured Expenses has averaged $997470.6 across 5 years, with a median of $990000.0 in 2024.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 1677.23% — and 2024, when it slumped 484.5%.
- Definium Therapeutics' Change in Accured Expenses stood at -$1.0 million in 2022, then jumped by 251.83% to $1.6 million in 2023, then jumped by 140.23% to $3.8 million in 2024, then tumbled by 75.62% to $923000.0 in 2025, then surged by 224.38% to $3.0 million in 2026.
- Business Quant data shows DFTX's Change in Accured Expenses at $3.0 million in Q1 2026, $923000.0 in Q4 2025, and $3.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Definium Therapeutics | 4.23 Bn | 4.23 Bn | - | 6.85 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.85 Mn |
| Mar 31, 2026 | 2.99 Mn |
| Dec 31, 2025 | 923,000.00 |
| Sep 30, 2025 | 3.36 Mn |
| Jun 30, 2025 | 3.01 Mn |
| Mar 31, 2025 | -1.33 Mn |
| Dec 31, 2024 | 3.79 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 990,000.00 |
| Mar 31, 2024 | -2.70 Mn |
| Dec 31, 2023 | 1.58 Mn |
| Sep 30, 2023 | -147,000.00 |
| Jun 30, 2023 | 3.19 Mn |
| Mar 31, 2023 | 703,000.00 |
| Dec 31, 2022 | -1.04 Mn |
| Sep 30, 2022 | -170,000.00 |
| Jun 30, 2022 | -202,000.00 |
| Mar 31, 2022 | 994,000.00 |
| Dec 31, 2021 | 7.52 Mn |
| Sep 30, 2021 | -5.47 Mn |